TAVR Market
Feb 08, 2024
Cerenovus Launched Next-Gen Stroke Revascularization Catheter; Dexcom Launched New ONE+ CGM System; Philips Received the US FDA Nod for Latest Intellivue Patient Monitor Software; Toku Obtained CE and UKCA Marks for AI Cardiovascular Risk Assessments; Genesis MedTech Completed Enrollment in TAVR Trial; Carthera’s Ultrasound Drug Delivery Trial
J&J’s Cerenovus Launched Next-Gen Stroke Revascularization Catheter On February 7, 2024, Johnson & Johnson MedTech’s Cerenovus announced the launch of its next-generation CereGlide 71 intermediate catheter with TruCourse indicated for the revascularization of patients suffering from acute ischemic stroke...
Read More...
Mar 31, 2022
Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies
Ypsomed Collaborated with CamDiab for Smartphone-based Automated Insulin Delivery On March 22, 2022, Ypsomed, a leading manufacturer of injection and infusion systems for self-medication partnered with CamDiab Ltd, developer of CamAPS FX, an app for the management of glucose levels via insulin pumps using an ada...
Read More...
Mar 29, 2021
Ever-Evolving Market Landscape of Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement (TAVR), also known as Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive surgery performed to insert a new valve without removing the damaged one. The narrowed aortic valve, which has failed to open properly (aortic valve stenosis), is replaced by a new on...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
